U.S. Renal Care Advances Kidney Care and Dialysis Innovation with Eight Studies at ASN Kidney Week 2026

Eight studies address important challenges affecting people receiving dialysis, including anemia management and catheter-related bloodstream infections

PLANO, Texas, Oct. 29, 2026 /PRNewswire/ -- U.S. Renal Care (USRC), the nation's largest privately held and fastest-growing kidney care provider, continues to advance kidney care through the presentation of eight studies at the American Society of Nephrology's (ASN) Kidney Week 2026.

This research comes at a transformational time in nephrology, as emerging treatment options, pharmaceutical therapies and preventive strategies to slow the progression of kidney disease and improve the lives of patients receiving dialysis are being rigorously evaluated and translated into clinical practice at U.S. Renal Care.

"At U.S. Renal Care and Satellite Healthcare, we are committed to bringing innovative therapies that address meaningful clinical outcomes to our patients," said Geoffrey A. Block, Associate Chief Medical Officer & Senior Vice President, Clinical Research & Medical Affairs. "We fundamentally believe it is our privilege and our obligation to advance the care of patients with kidney disease through the conduct of high-quality, meaningful clinical research."

U.S. Renal Care's Kidney Research team designs and conducts clinical trials, spanning across academic collaboration, investigator-initiated research, industry-sponsored research, and federally funded research.

U.S. Renal Care Kidney Research – 2026 ASN Kidney Week Presentations

LATE-BREAKING HIGH IMPACT CLINICAL TRIAL

Vadadustat Three Times Weekly for the Treatment of Anemia in Patients Receiving Hemodialysis

Shuchi Anand, Glenn M. Chertow, Myles Wolf, Mary O. Dittrich, Gopa Green, Martha Block, Adrian E. Elorriaga, Stephanie Brillhart, Amanda Leppink, F. David Newby, Carolina Arias, Ayodele Erinle, Irfan Agha, Geoffrey A. Block

ORAL PRESENTATIONS

Efficacy and Safety of Upacicalcet in Patients with Secondary Hyperparathyroidism (SHPT) on Hemodialysis: Two Randomized Controlled Clinical Trials (RCTs)

Jessica B. Kendrick, Myles Wolf, Biserka H. Tirmenstajn Jankovic, Aaron Camp, Eleanor Copeland, Bastian Dehmel, Geoffrey A. Block

Addressing the Home Dialysis Nurse Shortage: A Survey of Factors Influencing Recruitment and Retention in the United States

Lauren D. Stern, Nupur Gupta, Alexis Martin, Ronald L. Pisoni, Mia Gross, Joanna Neumann, Mihran V. Naljayan, Roberto Pecoits-Filho, Thao T. Pascual, Dinesh K. Chatoth, Jenny I. Shen

LATE-BREAKING POSTER

Real-World Effectiveness of Taurolidine/Heparin Catheter Lock Solution in Patients on Hemodialysis with Central Venous Catheters

Gopa Green, Glenn M. Chertow, Mary O. Dittrich, Martha Block, Stephanie Brillhart, Geoffrey A. Block

POSTER PRESENTATIONS

Trial in Progress: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating AP306 for Hyperphosphatemia in Patients Receiving Maintenance Hemodialysis

Geoffrey A. Block, Sharon M. Moe, Li Zuo, Markus Ketteler, Smeeta Sinha, Marie-Louise Trotman, Allison Lim, Weifeng Zhang, Huading Zhang, Gavin G. Xia, L. Mary Smith, Krishna Polu, Glenn M. Chertow

CKD-MBD Biomarker Profile in Patients on Hemodialysis with Secondary Hyperparathyroidism Treated with Upacicalcet: Biomarker Results from the Phase 3 PATH-1 and PATH-2 Trials

Thomas L. Nickolas, Bastian Dehmel, Geoffrey A. Block, Jessica B. Kendrick

Association of DefenCath Catheter Locking Solution Use with Reduced Rates of Catheter-Related Bloodstream Infections in Real-World Dialysis Centers

Sharada Weir, Jared L. Crandon, Martha Block, Geoffrey A. Block, Liz Hurlburt

A Phase 3 Study of AND017, a Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor, in Patients with Anemia Due to Nondialysis-Dependent CKD (NDD-CKD) in the United States

Yusha Zhu, Suzanne Wilson, Xiaolu Li, Qi Zhu, Geoffrey A. Block, Pablo E. Pergola

About U.S. Renal Care

U.S. Renal Care is the largest privately held and fastest-growing dialysis provider in the nation. We partner with nephrologists to care for more than 37,000 people living with kidney disease across 32 states, offering in-center and home dialysis options that support each patient's unique lifestyle and care needs. U.S. Renal Care leads the dialysis industry with the highest percentage of CMS 4- and 5-star rated centers for patient experience and quality of care. U.S. Renal Care's Kidney Research team designs and conducts clinical trials, spanning across academic collaboration, investigator-initiated research, industry-sponsored research, and federally funded research. Since 2000, U.S. Renal Care has grown through clinical excellence, innovation and a shared commitment to improving the lives of people with kidney disease. Visit USRenalCare.com to learn more.

SOURCE U.S. Renal Care